Jennifer Zachary - Merck General Counsel

MRK Stock  EUR 95.60  0.90  0.93%   

Executive

Ms. Jennifer Zachary is Executive Vice President, General Counsel of the Company, effective April 16, 2018. Zachary is currently a partner at Covington Burling in the firm food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA requirements for the development, manufacture, and distribution of prescription and overthecounter drugs, biologics, and medical devices. Zachary began her career in FDA Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney Office for the District of Columbia. since 2018.
Age 45
Tenure 6 years
Phone908 740 4000
Webhttps://www.merck.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
Merck Company has accumulated 27.59 B in total debt with debt to equity ratio (D/E) of 99.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merck Company has a current ratio of 1.19, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

EXECUTIVE Age

Michele LombardiCNH Industrial NV
N/A
Marc KermischCNH Industrial NV
N/A
Roberto RussoCNH Industrial NV
63
Federico DonatiCNH Industrial NV
N/A
Derek NeilsonCNH Industrial NV
N/A
Kevin BarrCNH Industrial NV
63
Erik LagendijkSBM Offshore NV
63
It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. MERCK INC operates under Drug Manufacturers - Major classification in Austria and is traded on Vienna Stock Exchange. It employs 69000 people. Merck Company (MRK) is traded on Vienna Exchange in Austria and employs 37 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cristal Downing, Ex Officer
Jennifer Zachary, General Counsel
David Williams, Ex Officer
Caroline Litchfield, Ex CFO
Lisa LeCointeCephas, VP Officer
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board and Presidentident, CEO
Peter Dannenbaum, VP Relations
Jennifer Mauer, VP Communications
Robert JD, Pres Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Merck Stock

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.